What makes SimonMed’s partnership with Lunit a turning point in clinical imaging?

A new chapter in AI-driven diagnostics may be unfolding as SimonMed Imaging teams up with South Korea–based artificial intelligence firm Lunit to bring large-scale foundation models into real-world radiology workflows. The American outpatient imaging giant, known for operating one of the most expansive radiology networks in the United States, has announced a strategic partnership with Lunit to fine-tune and deploy a chest X-ray foundation model built specifically from its own clinical data.

Unlike conventional AI models trained on generic datasets, this approach uses SimonMed’s internal imaging and reporting archives to customize Lunit’s CXR foundation model. The result is a highly adaptive, site-specific diagnostic tool designed to match the unique language, workflows, and clinical patterns used by more than 200 subspecialty-trained radiologists across SimonMed’s 175+ imaging centers in 11 states.

According to Founder and Chief Executive Officer Dr. John Simon, this partnership marks a key inflection point in radiology AI. He emphasized that the initiative enables the group to scale intelligent diagnostics while preserving radiologist expertise and oversight—a practical innovation aimed at boosting accuracy, speeding up turnaround times, and bringing greater consistency to patient care across the network.

How Lunit’s foundation model architecture supports local adaptation in healthcare AI deployments

The core innovation behind this initiative lies in the structure and scalability of foundation models. Unlike conventional AI tools that rely on narrow, pre-annotated datasets, foundation models are trained on vast multimodal datasets that include millions of clinical images and textual reports. This architecture captures a wide spectrum of domain knowledge, which can be further refined using local datasets to produce highly specialized models that reflect institutional practice.

Lunit’s Foundation Model Services platform allows imaging providers like SimonMed Imaging to take base models and fine-tune them in a secure, HIPAA-compliant environment using internal data. This ensures that the AI system is tailored not only to the clinical conditions of the patient population but also to the stylistic and procedural nuances of the institution’s radiologists. Model performance tracking and drift alerts are also built into the platform, enabling SimonMed to maintain quality and accountability even as case complexity or data volumes evolve.

Brandon Suh, Chief Executive Officer of Lunit, explained that this customization ability is essential for radiology, where diagnostic patterns and operational workflows vary significantly between providers. According to Suh, the deployment at SimonMed proves that large-scale AI adaptation is possible in weeks, not years, if the underlying model and platform are built to support such clinical variation.

What scalable AI means for SimonMed Imaging’s national operations and patient outcomes

With more than 175 locations across the United States, SimonMed Imaging faces the dual challenge of maintaining report consistency while handling large imaging volumes across modalities such as MRI, CT, PET/CT, 3D mammography, ultrasound, and nuclear medicine. The deployment of fine-tuned AI-generated reports specifically for chest X-rays is intended to serve as the first proof point in a much broader roadmap toward scalable diagnostic automation.

SimonMed is positioning this initiative not as a replacement for radiologists but as an enhancement layer that allows human experts to focus on more complex, nuanced interpretations while the AI handles high-volume, pattern-recognition–driven cases with improved speed and reliability. According to Dr. Simon, this blend of human expertise and machine precision could lead to more timely reporting, reduced error variability, and improved patient communication—especially in areas such as emergency or urgent care imaging.

The radiology provider has already built a reputation for early adoption of AI tools, particularly in breast imaging and brain disorder evaluation. Its simonONE division, which offers personalized imaging services for early disease detection, has also deployed AI-powered decision support tools across various diagnostic categories. The new chest X-ray model will likely be integrated with these systems, enabling a more unified approach to patient care.

What future models are planned as part of the SimonMed and Lunit collaboration roadmap

The chest X-ray foundation model is only the beginning of what both organizations view as a longer-term partnership to embed AI across diagnostic workflows. Lunit has confirmed that mammography and digital breast tomosynthesis models will be released in 2026 through the same Foundation Model Services platform, with additional multimodal models expected thereafter.

These future models are likely to target other high-volume diagnostic areas such as CT and MRI interpretation, with potential expansion into oncology screening, cardiovascular risk assessment, and precision diagnostics. Because the platform allows for modular deployment, SimonMed will be able to fine-tune and scale each model as needed, depending on regional imaging needs, patient demographics, and radiologist availability.

The long-standing relationship between SimonMed and Lunit suggests that this alliance could evolve into a broader clinical AI infrastructure initiative. Both firms have signaled that their focus will remain on scalable, privacy-compliant, and clinically grounded AI that integrates seamlessly into everyday diagnostic practice rather than offering one-size-fits-all solutions.

How Lunit is scaling its oncology AI footprint through digital pathology collaborations with Labcorp

The chest X-ray partnership comes on the heels of another major Lunit collaboration in oncology AI, this time with U.S.-based laboratory services giant Labcorp. Announced in November 2025, the collaboration aims to use Lunit’s SCOPE platform for digital pathology and spatial profiling to generate predictive biomarkers from tumor microenvironments.

Initial results from this partnership were presented at leading scientific forums such as the Society for Immunotherapy of Cancer and the Association for Molecular Pathology. One study demonstrated that Lunit’s algorithms could identify immune-active tumor phenotypes in non-small cell lung cancer patients with MET exon 14 skipping mutations, a subgroup that tends to respond better to immunotherapy. Another study confirmed that tumors with MET amplification tend to exhibit immune-desert characteristics, reinforcing the need for differential biomarker strategies in precision oncology.

Labcorp’s Vice President for Oncology, Dr. Shakti Ramkissoon, stated that AI-based spatial profiling enables researchers and clinicians to convert complex whole-slide pathology data into actionable insights. These findings could play a role in refining treatment decision-making, optimizing companion diagnostics, and accelerating the development of new immunotherapy targets.

Why foundation model customization and data privacy are critical for enterprise AI adoption in healthcare

One of the most critical features of this deployment model is its alignment with data privacy regulations and healthcare compliance. The ability to train models using local data without exposing it to external servers or vendors ensures full HIPAA compliance and gives providers like SimonMed Imaging greater control over their data governance strategies.

This localized training approach is not only a regulatory advantage but also a technical necessity. Generic AI models often fail to capture institutional-specific biases, imaging protocols, and language use, which can lead to inconsistent or even misleading outputs. Foundation models, when trained with in-house imaging and reporting data, avoid these pitfalls by learning directly from the provider’s clinical style and patient population characteristics.

The performance monitoring and drift detection features built into Lunit’s Foundation Model Services platform further reinforce this trust, ensuring that SimonMed can detect any deviations in model behavior early and retrain accordingly. This closed-loop system is essential in healthcare environments where diagnostic reliability and legal accountability are non-negotiable.

What are the key takeaways from the SimonMed Imaging and Lunit foundation model partnership?

• SimonMed Imaging is deploying one of the first large-scale, fine-tuned foundation models for chest X-ray report generation in partnership with South Korea–based medical AI firm Lunit.

• The model is trained using SimonMed’s own imaging and reporting data through Lunit’s Foundation Model Services platform, ensuring site-specific accuracy and workflow alignment across 175+ clinical sites.

• The deployment aims to enhance reporting consistency, speed, and quality while preserving radiologist oversight, marking a shift toward scalable AI integration in national outpatient imaging networks.

• Lunit’s platform enables fine-tuning within HIPAA-compliant environments, maintaining data privacy and supporting continuous model performance monitoring through drift alerts.

• Future models for mammography and digital breast tomosynthesis are scheduled for 2026, with broader multimodal expansion expected to follow.

• This collaboration is part of SimonMed Imaging’s ongoing strategy to blend AI with clinical operations, building on its simonONE personalized imaging services and prior AI deployments in breast and brain diagnostics.

• Lunit is simultaneously expanding its oncology AI footprint through a digital pathology collaboration with Labcorp, targeting immune biomarker discovery in lung cancer using spatial profiling and machine learning.

• Early study results from the Labcorp alliance presented at SITC and AMP show Lunit’s AI can differentiate tumor microenvironments by MET mutation status in NSCLC, supporting immunotherapy stratification.

• The SimonMed–Lunit alliance reflects a broader industry trend toward localized, institution-specific AI deployment in radiology and oncology, emphasizing adaptability, scalability, and clinical relevance.

• Both organizations are aligning innovation with real-world diagnostic practice, creating a replicable model for future enterprise-grade AI rollouts in healthcare.